A Mini Review of Trends towards Automated and Non-Invasive Techniques for Early Detection of Lung Cancer: From Radiomics through Proteogenomics to Breathomics

Funmilayo S. Moninuola¹, Emmanuel Adetiba¹,², Oluwadamilola I. Oshin¹, Anthony A. Atayero¹ and Ademola Adeyeye³

¹Department of Electrical and Information Engineering, Covenant University, Nigeria
²HRA, Institute for Systems Science, Durban University of Technology, Durban, P.O. Box 1334, Durban, South Africa.
³Division of Oncology, Department of Surgery, Afe Babalola University, Ado-Ekiti, Nigeria
Corresponding Author: emmanuel.adetiba@covenantuniversity.edu.ng

Abstract

Carcinoma of the Lung is one of the most common cancers in the world and the leading cause of tumor-related deaths. Less than 15% of patients survive 5 years post diagnosis due to its relatively poor prognosis. This has been ascribed to lack of effective diagnostic methods for early detection. Different medical imaging techniques such as chest radiography, Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are used in routine clinical practice for tumor detection. These techniques are medically unsatisfactory and inconvenient for patients due to poor diagnostic accuracy. Endobronchial biopsies are the gold standard for diagnosis but have the inherent risk of full or partial invasive procedures. Thus, diagnostic technology that uses data mining algorithms with medical image analysis, generally known as radiomics emerged. Radiomics extracts complex information from conventional radiographic images and quantitatively correlates image features with diagnostic and therapeutic outcomes. In spite of the benefits, radiomics is prone to high false positives and there is no established standard for acquisition of parameters. Further efforts towards outcome improvement led to the proteomic and genomic (proteogenomic) approach to lung cancer detection. Although proteogenomic has a diagnostic edge over traditional techniques, variations in bio-specimen and heterogeneity of lung cancer still possess a major challenge. Recent findings have established that changes normally occur in the gene or protein due to tumor growth in the lungs and this often leads to peroxidation of cell membrane that releases Volatile Organic Compounds (VOCs) through the breath of Lung Cancer patients. The comprehensive analysis of breath VOCs, which is tagged Breathomics in the literature, unveils opportunities for noninvasive biomarker discovery towards early detection. Breathomics has therefore become the current pace-setter in medical diagnostics research because of its non-invasiveness and cost effectiveness. This paper presents a mini survey of trends in early lung cancer detection from radiomics, through proteogenomic to breathomics.

Keywords: Breathomics, CT, Early Detection, Lung Cancer, MRI, Proteogenomic, Radiomics.
1. Introduction

Lung Cancer (LC), also known as lung carcinoma or bronchogenic carcinoma, is a virulent lung sarcoma formed by unrestrained cell growth in the tissues of the lung. LC is the most common cause of cancer deaths worldwide and the sixth principal cause of death among all cancer types in Africa [1-3]. Therapeutic regimens were once independent of subtype but became a concern as the understanding of phenotypic differences in tumors improved over the years [4, 5]. The current 5-year survival rate for lung cancer is 15%. Furthermore, only 16% of lung cancer cases are discovered when localized while 22% and 57% are diagnosed at regional and distant stages respectively. Despite the knowledge that early detection of lung cancer would have a significant impact on survival rates, there has not been an effective screening test that yields results as obtainable for other cancer types such as breast and colorectal [6, 7]. The gold standard for the diagnosis of LC is tissue analysis acquired via some form of biopsy, typically endobronchial. This method is invasive and cannot be used in the general population.

Studies show that traditional methods for initial LC detection includes the use of medical imaging approach such as Positron Emission Tomography (PET), Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Low-Dose CT (LDCT), and Chest Radiograph (CRG) scans. Most of all these methods are time consuming, expensive, potentially hazardous (in terms of radiation exposure) and are less sensitive in detecting cancerous cells at the early stage in addition to their invasiveness [1, 8-10]. Recent advances in medical image processing has led to the development of non-invasive diagnosis that leverages on these imaging techniques. For instance, radiomic approach involves extracting radiographic image data of the lung into mineable features with high resolution, using a large amount of robotically extracted data-characterization algorithms. Nevertheless, one of the problems with radiomics is that the radiographic images do not show the complexity of tumor morphology that affects the region of interest [11]. Several investigators have shown that gene expression of normal lung tissues can be distinguished from the cancerous ones by simultaneous profiling of the protein and gene expression of LC tumor, typically referred to the proteogenomic approach. The main challenge of this method is the limited training data samples of proteins and genes as they are gathered from fewer subjects while the protein and gene expressions in each sample is usually unlimited [10]. A screening procedure that can discover lung cancer at onset before it spreads is advantageous in reducing lung cancer morbidity and mortality and consequently heightens the chances of successful treatment. It has been established in the literature that human exhaled breath contains over 3,000 Volatile Organic (VOC) such as chain, alicyclic and aromatic hydrocarbons. These VOCs are likely biomarkers of several pulmonary diseases, including LC. The analysis of exhaled breath to infer the health status of a human subject is referred to as breathomics. Its major strengths over other approaches for early detection and screening of pulmonary diseases is that it is inexpensive and non-invasive [12]. Thus, a non-invasive breath test has immense potential as a lung cancer examination method.
2.0 Evolution of Existing Approaches for Early Detection of Lung Cancer

The quest for early detection of lung cancer, has led to different novel modalities with progressive improvement in the level of sensitivity, specificity and reduction in the rate of false negatives and false positives. Each of the existing approaches have specific benefits and potential drawbacks. There is therefore a need to understand their various roles in LC screening as reported in the literature.

2.1 Radiomics

The conventional screening and detection methods for lung cancer include; CRG, CT, LDCT, MRI and PET. These procedures are aimed at detecting nodules in subjects that are highly prone to lung cancer. Although they are well known methods with a large pool of experienced users, they are beset with demerits [13, 14]. Physicians and Radiologists find it difficult to identify cancerous nodules when analyzing ordinary radiographic image because the cross section is complex. This demands additional work by the radiologists in detecting the lung cancer and therefore there is a high probability of error. Radiomics is the development of processes and techniques for high-resolution extraction of quantitative features that convert images from the conventional imaging methods into datasets, which could be mined for clinical decision supports [15]. Computer Aided Diagnosis (CAD) method was developed to assist physicians and radiologists to precisely examine the radiographic scans in order to increase the accuracy of neoplasm nodule detection. Several studies [16], [17] showed that using radiomics has substantially improved the performance of automated analysis of radiological images. Thus, radiologists use the computer output to double check before making final decisions because the system is considered useful for detection of potential nodules [11]. Segmentation, feature extraction, classification and nodule detection are the main stages employed in radionics. Original radiographic images of subjects are obtained from database of LC screening radiographic images with marked-up annotated lesions such as Lung Image Database Consortium (LIDC) [18, 19]. The performance of the procedure is not easy to determine due to variation in image utilized. Also, a lack of integration between the radiologist and CAD systems can restrain the rate of progress. In fact, most of the proposed models reported in the literature could not classify the cancer as benign or malignant. Also, lack of prior information about the region of interest for preprocessing sometimes lead to incorrect decision or errors of omission.

2.2 Proteomics and Genomics

Proteomics is a detail investigation of all set of proteins found in tissue, gene, or cell. This technology profiles how disease changes the structure of protein. Protein structure changes from a healthy to cancerous cell when there is a modification or alteration in protein complement which may affect the structure and function of the cell.

Genomics and Proteomics are used for synchronized investigation of the genes and proteins
respectively, that are expressed in a specified gene, cell or tissue type and also identify new molecular targets. The simultaneous profiling of molecular expression of the gene and proteins tumor uses microarray technology. Lung cancer-associated proteins are generated by lung cancer tissues. In turn, the immune system tends to produce high-affinity auto-antibodies to these proteins. Blood biomarkers contain unique proteins and auto-antibodies to tumor-associated antigens that might be detectable 1–3 years preceding clinical diagnosis [20, 21]. Previous Studies used an algorithmic solution for binary classifications of LC biomarkers. According to Broodman [22], some widely-known and clinically utilized lung cancer protein biomarkers are carcinoembryonic antigen (CEA), CYFRA 21-1 (cytokeratine 19 fragment), Neuron-Specific Enolase (NSE), Progastrin Releasing Peptide (ProGRP), and Squamous Cell Carcinoma Antigen (SCCA). Antigen-125 (CA-125), Human Epididymis protein 4 (HE4) and surfactant form of protein B (Pro-SFTPB) are other lung cancer protein biomarkers [23, 24]. A study by Adetiba et al. [25], showed that lung cancer can be predicted using neural network ensembles with histogram of oriented gradient genomic features.

Furthermore, the acclaimed Protein Pathway Array (PPA) analysis method that allows the identification of important, but low abundance proteins and phosphoproteins in Lung Cancer has been developed [26, 27] [28, 29]. Poor sensitivity to low marker concentration is one of the downsides of this approach. The process also consumes a lot of time and money. Moreover, the available data to test the performance of these biomarkers for subsequent lung cancer cases and control discrimination is not sufficiently available [30].

2.3 Breathomics

Breath analysis is a state-of-the-art method for early disease detection that is also known as Breathomics. According to Smolinska et al. [31], the purpose of Breathomics studies is to discover patterns in Volatile Organic Compound (VOC) that underlie abnormal metabolic processes in humans.

Breath research started about fifty decades ago when Pauling used gas chromatography procedure to prove that human breath is made up of about two hundred and fifty gases [32]. The application of machine intelligence techniques (such as machine learning) to analyze the “fingerprint” (breathprint or breath signature) of VOC patterns in Breathomics is still at its infancy [31].

Anatomization of breath can be employed in medical examination and ecological assessment because it is non-invasive.

A lot of molecules are released into the atmosphere during respiration. Breath is composed a combination of inorganic gas, inert gas and small fraction of VOCs concentration in the range of parts per million (ppm) to parts per trillion (ppt) by volume. VOCs are generated through endogenous or exogenous processes and its constitution quantitatively and qualitatively are not the same in individuals.
O’Neill et al. [33] reported that the exhaled breath of lung cancer patients contains twenty-eight biomarkers such as: lipid-peroxidation, hexane, aniline methlpentane and o-toluidine cancer [33-35].

A systematic analysis of VOCs by Phillips et al. [36] also affirm the difference in the breath of lung cancer and healthy subjects by suggesting alkanes and benzene derivatives among twenty-two VOCs for early detection of lung cancer.

Not fewer than three thousand VOCs are found in healthy humans’ breath till date, only Isoprene, Ethane, Pentane, Acetone and few are common to everyone. VOCs occurs as a result of metabolic processes and are instructive in medical prognosis [36-40].

Since lung cancer cells have unique metabolic properties, metabolic activity within the body mirrors the composition of VOCs in the exhaled breath. These metabolic by-products circulate within the blood and transfer to the lungs where they are exhaled from the body. This implies that variations in the body’s metabolic procedures result in unique VOC prints or signatures. Thus, authors have suggested that disease-specific metabolism can be detected as breath signatures (breathprint) signifying the presence of lung cancer from the analysis of exhaled breath of lung cancer patients [35, 41, 42]. The exhaled breath can be examined based on two unique albeit interrelated methods: Chemical Analysis of VOCs (VOC identification) and Electronic Nose based VOC Analysis (VOC patterning). Although the chemical analysis methods are capable of early detection of lung cancer, they are not portable, they have no ease of use and cannot be used at the Point-of-Care (POC) in the clinic or homes [43, 44]. Thus, this mini review addresses the Electronic Nose based VOC Analysis as a breathomics approach.

### 2.3.1 Electronic Nose

The Electronic Nose (E-nose) approach to VOC analysis overcomes the limitations of the chemical analysis approach through qualitative and pattern-based “breathprint” systems. The contrast of the human olfactory system and E-nose is presented diagrammatically in Fig.1. As shown in the upper part of the figure, E-Nose is made up of a sensing sub-system, which is the hardware and the automated pattern recognition sub-system. The sensing system is made up of an array of sensors where each sensor detects a specific biomarker based on the chemical properties and then converts it to an electrical signal to form a signature or pattern. The signature of each biomarker is then used to build a database of labeled signatures that is used to train a pattern recognition system to form an intelligent system. The E-nose is subsequently applied to classify unknown samples to differentiate the VOC biomarkers. Principal Component Analysis (PCA) is mostly used for feature projection while the pattern recognition units currently in use are supervised pattern classification algorithms such as k-Nearest Neighbors (k-NN), Support Vector Machine (SVM) and Artificial Neural Network (ANN) [45]. E-nose as a breathomics method has huge potentials to support PoC-based early diagnosis of lung cancer. This method is inexpensive, non-invasive, has a speedy response time and has a generally portable system.
3.0 Result and Discussion

Tables 1, 2 and 3 presents the literature matrices of selected existing studies that are based on radiomics, proteogenomics and breathomics respectively. In table 1, a literature matrix of some radiomics research work is shown where different database and methodologies were used for lung nodules detection and classification. Due to the sensitivity of this approach to image analysis, there is a need for standardization of the machine learning techniques involved in radiomics analysis of lung nodules images. Table 2 highlights matrix of some proteogenomics research work where different biomarkers, tumor types and groups of patients were investigated for early detection of LC. Like radiomics, there is no resolution on the type of biomarkers or composition of the biomarkers and the technology that should be focused on for early detection of LC.

Table 1: Literature Matrix of Some Radiomics Approaches

| S/N | Database | Segmentation Method | Classifier | Sensitivity (%) | Reference |
|-----|----------|---------------------|------------|-----------------|-----------|
| 1   | LIDC     | Watershed segmentation | SVM      | 92              | [46]      |
| 2   | LIDC/IDRI| Watershed clustering | SVM, Naïve Bayes and FLD Multiview | 94.4     | [19]      |
| 3   | LIDC/IDRI| Structural LDA, gradient boosting (GB 10) | Convolutional Network SVM | 90.1     | [47]      |
| 4   | LIDC, ELCAP| Discrete wavelet transforms | SVM | 90.9       | [48]      |
| 5   | LIDC/IDRI| Rule based Structural | SVM | 93.6     | [18]      |
| 6   | LIDC/IDRI| Selective filter based (vessel) | Rule based classification (RBC) | 82       | [49]      |
| 7   | Private  | Cylindrical filter and thresholding based | Support Vector Machine | 90       | [50]      |
| 8   | Private  |                      |            | 90              | [51]      |
Table 2: Literature Matrix of Some Proteogenomics Approaches

| S/N | Biomarker       | Tumor Type                                      | Sensitivity % | Reference |
|-----|-----------------|-------------------------------------------------|---------------|-----------|
| 1   | DNA methylation | 54 NSCLC adjacent normal tissues                | 85.2          | [55]      |
| 2   | DNA methylation | 138 formalin-fixed - 116 LC and 22 controls      | 100           | [56]      |
| 3   | miRNA biomarkers | Exosomes from BAL 4 Tissue samples 13 AC vs. 15 controls | NA           | [57]      |
| 4   | Proteomic       | -BAL -139 lung cancer and 49 controls -43 SCLC and 96 NSCLC | 95           | [58]      |
| 5   | Proteomic       | - Tissue – 13 NSCLC 6 AC and. 7 SCC - BAL - 90 suspected lung cancer prospectives followed for two years - Tissue | NA           | [59]      |
| 6   | Proteomic       |                                                   | NA           | [60]      |
| 7   | Liquid biopsy   | -108 patients with malignant nodules and -113 patients with benign lung nodules | 75           | [61]      |
| 8   | DNA methylation | Plasma and sputum 150 NSCLC - 60 Control Sputum - 98 Plasma - 93 |               | [62]      |
| 9   | Proteomic       | - Tissue - 14 AC vs. adjacent normal tissue     | NA           | [63]      |
Deoxyribonucleic acid (DNA), microribonucleic acid (miRNA), bronchoalveolar lavage (BAL), Not Available (NA), Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma (AC), Squamous Cell Carcinoma (SCC)

Table 3: Literature Matrix of Some Breathomics (E-nose) Approach

| S/N | Sensor Type | Classifier | Accuracy (%) | Reference |
|-----|-------------|------------|--------------|-----------|
| 1   | MOS         | Multilayer Perceptron (MPL) | 75           | [65]      |
| 2   | MOS         | ANN        | 83           | [43]      |
| 3   | MOS         | PCA-KNN    | 8.4          | [66]      |
| 4   | Cyranose 320 sensor | SVM      | 87.3         | [67]      |
| 5   | Silicon nanowire Field Effect Transistor (SiNW FET) | ANN | 84 | [68] |
| 6   | QMB         | PLS-DA     | 93           | [69]      |
| 7   | Colorimetric sensor array | Logistic prediction model | 81 | [70] |
| 8   | Metalloporphyrin s-coated QCM sensors | PLS-DA | 75 | [71] |
| 9   | Organically functionalized Au nanoparticle | PCA | 86 | [72] |

MOS - Metal Oxide Sensor, QMB-quartz microbalance

It is apparent from the mini review at hand that analyzing breathprints of a lung cancer patient (breathomics) at an early stage offers several potential advantages over the radiomics and proteogenomics approaches [25, 57, 58, 73-76], which include:
i. Exhaled-breath analysis is highly informative and a totally non-invasive alternative to current proteogenomics and culture-based methods.

ii. In contrast to other specimen, breath can easily be collected, as many times as required.

iii. The measurement of gas-phase analytes is simpler in a gas matrix (breath) than in more complex biological matrices.

iv. It is easy to obtain and painless to the individual with no undesirable side effects.

v. Breath analysis has great potential for direct and real-time diagnosis and monitoring.

4.0 Conclusion

E-nose-based breathomics approach is a very promising method for early disease detection. In addition to the afore mentioned advantages, it is noteworthy that even though the sensitivity/accuracy of this breathomics approach is generally a bit less than the two previous approaches, it yields comparable results even at its infancy stage. This suggests its potential with more research in the coming years.

Acknowledgement

The publication of this research paper is fully sponsored by Covenant University Centre for Research, Innovation and Development (CUCRID), Covenant University, Ota, Nigeria.

References

[1]. Bray, F., Jemal, A., Grey, N., Ferlay, J., & Forman, D. (2012). Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. The Lancet Oncology, 13(8), 790-801

[2]. Mathers, C. D., & Loncar, D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS medicine, 3(11), e442.

[3]. Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H., Beasley, M. B., . . . Flieder, D. B. (2015). The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. Journal of Thoracic Oncology, 10(9), 1243-1260.

[4]. Ho, C., Tong, K., Ramsden, K., Jonescu, D., & Laskin, J. (2015). Histologic classification of non-small-cell lung cancer over time: reducing the rates of notOtherwise-specified. Current oncology, 22(3), e164.

[5]. Rizvi, N. A., Hellmann, M. D., Brahmer, J. R., Juergens, R. A., Borghaei, H., Gettinger, S., . . . Antonia, S. (2016). Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced NonSmall-Cell Lung Cancer. Journal of Clinical Oncology, 34(25), 2969-2979. doi: 10.1200/jco.2016.66.9861

[6]. Barash, O., Peled, N., Tisch, U., Bunn, P. A., Hirsch, F. R., & Haick, H. (2012). Classification of lung cancer histology by gold nanoparticle sensors. Nanomedicine:
Nanotechnology, Biology and Medicine, 8(5), 580-589. doi: https://doi.org/10.1016/j.nano.2011.10.001

[7]. Lanni Jr, T. B., Stevens, C., Farah, M., Boyer, A., Davis, J., Welsh, R., . . . Mezwa, D. (2018). Early results from the implementation of a lung cancer screening program: the Beaumont Health System Experience. American journal of clinical oncology, 41(3), 218-222.

[8]. Barón, A. E., Kako, S., Feser, W. J., Malinowski, H., Merrick, D., Garg, K., . . . Varella-Garcia, M. (2017). Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. Journal of Thoracic Oncology, 12(10), 1512-1523. doi: https://doi.org/10.1016/j.jtho.2017.06.008

[9]. Patz, E. F., Pinsky, P., Gatsonis, C., Sicks, J. D., Kramer, B. S., Tammemägi, M. C., . . . Aberle, D. R. (2014). Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA internal medicine, 174(2), 269-274.

[10]. Lotfi, E., & Keshavarz, A. (2014). Gene expression microarray classification using PCA–BEL. Computers in biology and medicine, 54, 180-187.

[11]. Ferreira Junior, J. R., Koenigkam-Santos, M., Cipriano, F. E. G., Fabro, A. T., & Azevedo-Marques, P. M. d. (2018). Radiomics-based features for pattern recognition of lung cancer histopathology and metastases. Computer Methods and Programs in Biomedicine, 159, 23-30. doi: https://doi.org/10.1016/j.cmpb.2018.02.015

[12]. Rocco, G., Pennazza, G., Santonico, M., Longo, F., Rocco, R., Crucitti, P., & Incalzi, R. A. (2018b). Breathprinting and early diagnosis of lung cancer. Journal of thoracic oncology. 13(7), 883-894.

[13]. de Koning, H. J., Meza, R., Plevritis, S. K., & et al. (2014). Benefits and harms of computed tomography lung cancer screening strategies: A comparative modeling study for the u.s. preventive services task force. Annals of Internal Medicine, 160(5), 311-320. doi: 10.7326/M13-2316

[14]. Kovalchik, S. A., Tammemagi, M., Berg, C. D., Caporaso, N. E., Riley, T. L., Korch, M., . . . Katki, H. A. (2013). Targeting of low-dose CT screening according to the risk of lung-cancer death. New England Journal of Medicine, 369(3), 245-254.

[15]. Gillies, R. J., Kinahan, P. E., & Hricak, H. (2015). Radiomics: images are more than pictures, they are data. Radiology, 278(2), 563-577.

[16]. Orozco, H. M., Villegas, O. O. V., Maynez, L. O., Sánchez, V. G. C., & Dominguez, H. d. J. O. (2012). Lung nodule classification in frequency domain using support vector machines. Paper presented at the Information Science, Signal Processing and their Applications (ISSPA), 2012 11th International Conference on.

[17]. Kumar, S. A., Ramesh, J., Vanathi, P., & Gunavathi, K. (2011). Robust and automated lung nodule diagnosis from CT images based on fuzzy systems. Paper presented at the Process automation, control and computing (PACC), 2011 international conference on.

[18]. Demir, Ö., & Yılmaz Çamurcu, A. (2015). Computer-aided detection of lung nodules using outer surface features. Bio-medical materials and engineering, 26(s1), S1213-S1222.

[19]. Firmino, M., Angelo, M., Morais, H., Dantas, M. R., & Valentim, R. (2016). Computer-aided detection (CADe) and diagnosis (CADx) system for lung cancer with likelihood of malignancy. Biomedical engineering online. 15(1), 2.

[20]. Jain, K. K. (2016). Chapter Two - Role of Proteomics in the Development of Personalized Medicine. In R. Donev (Ed.), Advances in Protein Chemistry and Structural Biology (Vol. 102, pp. 41-52): Academic Press.
[21]. Zhong, L., Coe, S. P., Stromberg, A. J., Khattar, N. H., Jett, J. R., & Hirschowitz, E. A. (2006). Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. *Journal of Thoracic Oncology, 1*(6), 513-519.

[22]. Broodman, I., Lindemans, J., van Sten, J., Bischoff, R., & Luider, T. (2016). Serum protein markers for the early detection of lung cancer: a focus on autoantibodies. *Journal of Proteome Research, 16*(1), 3-13.

[23]. Sin, D. D., Tammemagi, C. M., Lam, S., Barnett, M. J., Duan, X., Tam, A., . . . Hanash, S. (2013). Pro–Surfactant Protein B As a Biomarker for Lung Cancer Prediction. *Journal of Clinical Oncology, 31*(36), 4536.

[24]. Taguchi, A., Hanash, S. M., Rundle, A. G., McKeague, I. W., Tang, D. L., Darakjy, S., . . . Perera, F. (2013). Circulating pro-surfactant protein B as a risk biomarker for lung cancer. *Cancer Epidemiology and Prevention Biomarkers*, cebp. 0251.2013.

[25]. Adetiba, E., & Olugbara, O. O. (2015). Lung cancer prediction using neural network ensemble with histogram of oriented gradient genomic features. *The Scientific World Journal, 2015*.

[26]. Liu, W., Wu, Y., Wang, L., Gao, L., Wang, Y., Liu, X., . . . Bayer, T. A. (2014). Protein signature for non-small cell lung cancer prognosis. *American journal of cancer research, 4*(3), 256.

[27]. Wang, D., Ye, F., Sun, Y., Li, W., Liu, H., Jiang, J., . . . Zhang, D. Y. (2011). Protein Signatures for Classification and Prognosis of Gastric Cancer: A Signaling Pathway-Based Approach. *The American Journal of Pathology, 179*(4), 1657-1666. doi: https://doi.org/10.1016/j.ajpath.2011.06.010

[28]. Li, W., Ye, F., Wang, D., Sun, X., Tong, W., Lian, G., . . . Zhang, D. Y. (2013). Protein predictive signatures for lymph node metastasis of gastric cancer. *International journal of cancer, 132*(8), 1851-1859.

[29]. Pass, H. I., Beer, D. G., Joseph, S., & Massion, P. (2013). Biomarkers and Molecular Testing for Early Detection, Diagnosis, and Therapeutic Prediction of Lung Cancer. *Thoracic Surgery Clinics, 23*(2), 211-224. doi: https://doi.org/10.1016/j.thorsurg.2013.01.002

[30]. Guida, F., Sun, N., Bantis, L. E., Muller, D. C., Li, P., Taguchi, A., . . . Yan, Q. (2018). Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. *JAMA oncology*, e182078-e182078.

[31]. Boots, A. W., van Berkel, J. J., Dallinga, J. W., Smolinska, A., Wouters, E. F., & van Schooten, F. J. (2012). The versatile use of exhaled volatile organic compounds in human health and disease. *Journal of breath research, 6*(2), 027108.

[32]. Pauling, L., Robinson, A. B., Teranishi, R., & Cary, P. (1971). Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. *Proceedings of the National Academy of Sciences, 68*(10), 2374-2376.

[33]. O'neill, H., Gordon, S., O'neill, M., Gibbons, R., & Szidon, J. (1988). A computerized classification technique for screening for the presence of breath biomarkers in lung cancer. *Clinical chemistry, 34*(8), 1613-1618.

[34]. Gordon, S., Szidon, J., Krotoszynski, B., Gibbons, R., & O'neill, H. (1985). Volatile organic compounds in exhaled air from patients with lung cancer. *Clinical chemistry, 31*(8), 1278-1282.
[35]. Sponring, A., Filipiak, W., Ager, C., Schubert, J., Miekisch, W., Amann, A., & Troppmair, J. (2010). Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells. *Cancer Biomark*, 7.

[36]. Phillips, M., Gleeson, K., Hughes, J. M. B., Greenberg, J., Cataneo, R. N., Baker, L., & McVay, W. P. (1999). Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. *The Lancet*, 353(9168), 1930-1933.

[37]. Horvath, I., Hunt, J., & Barnes, P. (2005). Exhaled breath condensate: methodological recommendations and unresolved questions. *European Respiratory Journal*, 26(3), 523-548.

[38]. Mochalski, P., Sponring, A., King, J., Unterkofler, K., Troppmair, J., & Amann, A. (2013). Release and uptake of volatile organic compounds by human hepatocellular carcinoma cells (HepG2) in vitro. *Cancer Cell International*, 13(1), 72. doi: 10.1186/1475-2867-13-72

[39]. Phillips, M., Cataneo, R. N., Cummin, A. R., Gagliardi, A. J., Gleeson, K., Greenberg, J., . . . Rom, W. N. (2003). Detection of Lung Cancer With Volatile Markers in the Breatha. *Chest*, 123(6), 2115-2123.

[40]. Rocco, G., Pennazza, G., Santonico, M., Longo, F., Rocco, R., Crucitti, P., & Incalzi, R. A. (2018a). Breathprinting and early diagnosis of lung cancer. *Journal of Thoracic Oncology*. doi: https://doi.org/10.1016/j.jtho.2018.02.026

[41]. Jordan, K. W., Adkins, C. B., Su, L., Halpern, E. F., Mark, E. J., Christiani, D. C., & Cheng, L. L. (2010). Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue–serum pairs. *Lung Cancer*, 68(1), 44-50. doi: https://doi.org/10.1016/j.lungcan.2009.05.012

[42]. An, Z., Chen, Y., Zhang, R., Song, Y., Sun, J., He, J., . . . Abliz, Z. (2010). Integrated Ionization Approach for RRLC–MS/MS-based Metabonomics: Finding Potential Biomarkers for Lung Cancer. *Journal of Proteome Research*, 9(8), 4071-4081. doi: 10.1021/pr100265g

[43]. van de Goor, R., van Hooren, M., Dingemans, A.-M., Kremer, B., & Kross, K. (2018). Training and Validating a Portable Electronic Nose for Lung Cancer Screening. *Journal of Thoracic Oncology*. doi: https://doi.org/10.1016/j.jtho.2018.01.024

[44]. Schmidt, K., & Podmore, I. (2015). Current challenges in volatile organic compounds analysis as potential biomarkers of cancer. *Journal of biomarkers, 2015*.

[45]. Estakhroyeh, H. R., Rashedi, E., & Mehran, M. (2017). Design and Construction of Electronic Nose for Multi-purpose Applications by Sensor Array Arrangement Using IBGSA. *Journal of Intelligent & Robotic Systems*, 1-17.

[46]. Makaju, S., Prasad, P., Alsadoon, A., Singh, A., & Elchouemi, A. (2018). Lung cancer detection using ct scan images. *Procedia Computer Science*, 125, 107-114.

[47]. Setio, A. A. A., Ciompi, F., Litjens, G., Gerke, P., Jacobs, C., Van Riel, S. J., . . . van Ginneken, B. (2016). Pulmonary nodule detection in CT images: false positive reduction using multi-view convolutional networks. *IEEE transactions on medical imaging*, 35(5), 1160-1169.

[48]. Orozco, H. M., Villegas, O. O. V., Sánchez, V. G. C., Domínguez, H. d. J. O., & Alfaro, M. d. J. N. (2015). Automated system for lung nodules classification based on wavelet feature descriptor and support vector machine. *Biomedical engineering online*, 14(1), 9.
[49]. Jacobs, C., van Rikxoort, E. M., Murphy, K., Prokop, M., Schaefer-Prokop, C. M., & van Ginneken, B. (2016). Computer-aided detection of pulmonary nodules: a comparative study using the public LIDC/IDRI database. *European Radiology, 26*(7), 2139-2147.

[50]. Jia, T., Zhang, H., & Meng, H. (2014). A novel lung nodules detection scheme based on vessel segmentation on CT images. *Bio-medical materials and engineering, 24*(6), 3179-3186.

[51]. Teramoto, A., Fujita, H., Takahashi, K., Yamamuro, O., Tamaki, T., Nishio, M., & Kobayashi, T. (2014). Hybrid method for the detection of pulmonary nodules using positron emission tomography/computed tomography: a preliminary study. *International Journal of Computer Assisted Radiology and Surgery, 9*(1), 59-69. doi: 10.1007/s11548-013-0910-y

[52]. Choi, W.-J., & Choi, T.-S. (2013). Automated pulmonary nodule detection system in computed tomography images: A hierarchical block classification approach. *Entropy, 15*(2), 507-523.

[53]. Chen, S., & Suzuki, K. (2013). Computerized detection of lung nodules by means of “virtual dual-energy” radiography. *IEEE Transactions on Biomedical Engineering, 60*(2), 369-378.

[54]. Keshani, M., Azimifar, Z., Tajeripour, F., & Boostani, R. (2013). Lung nodule segmentation and recognition using SVM classifier and active contour modeling: A complete intelligent system. *Computers in Biology and Medicine, 43*(4), 287-300.

[55]. Liu, F., Zhang, H., Lu, S., Wu, Z., Zhou, L., Cheng, Z., . . . Mao, H. (2018). Quantitative assessment of gene promoter methylation in non-small cell lung cancer using methylation-sensitive high-resolution melting. *Oncology letters, 15*(5), 7639-7648.

[56]. Walter, R., Rozynek, P., Casjens, S., Werner, R., Mairinger, F., Speel, E., . . . Theegarten, D. (2018). Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer. *PloS one, 13*(5), e0195716.

[57]. Kim, J. E., Eom, J. S., Kim, W. y., Jo, E. J., Mok, J., Lee, K., . . . Kim, M. h. (2018). Diagnostic value of microRNAs derived from exosomes in bronchoalveolar lavage fluid of early-stage lung adenocarcinoma: A pilot study. *Thoracic cancer, 9*(8), 911-915.

[58]. Uribarri, M., Hormaeche, I., Zalacain, R., Lopez-Vivanco, G., Martinez, A., Nagore, D., & Ruiz-Argüello, M. B. (2014). A new biomarker panel in bronchoalveolar lavage for an improved lung cancer diagnosis. *Journal of thoracic oncology, 9*(10), 1504-1512.

[59]. Nan, Y., Du, J., Ma, L., Jiang, H., Jin, F., & Yang, S. (2017). Early Candidate Biomarkers of Non–Small Cell Lung Cancer Are Screened and Identified in Premalignant Lung Lesions. *Technology in cancer research & treatment, 16*(1), 66-74.

[60]. Carvalho, A. S., Cuco, C. M., Lavareda, C., Miguel, F., Ventura, M., Almeida, S., . . . Seixas, S. (2017). Bronchoalveolar lavage proteomics in patients with suspected lung cancer. *Scientific reports, 7*, 42190.

[61]. Shen, J., Liu, Z., Todd, N. W., Zhang, H., Liao, J., Yu, L., . . . Zhan, M. (2011). Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. *BMC cancer, 11*(1), 374.

[62]. Hulbert, A., Jusue-Torres, I., Stark, A., Chen, C., Rodgers, K., Lee, B., . . . Wrangle, J. (2017). Early detection of lung cancer using DNA promoter hypermethylation in plasma and sputum. *Clinical Cancer Research, 23*(8), 1998-2005.
[63]. C.-H. Hsu, C.-W. Hsu, C. Hsueh, C.-L. Wang, Y.-C. Wu, C.-C. Wu, et al., "Identification and characterization of potential biomarkers by quantitative tissue proteomics of primary lung adenocarcinoma," Molecular & Cellular Proteomics, vol. 15, pp. 2396-2410, 2016.

[64]. Bagheri, A., Khorshid, H. R. K., Tavallaie, M., Mowla, S. J., Sherafatian, M., Rashidi, M., . . . Hosseini, S. M. (2019). A panel of noncoding RNAs in non–small-cell lung cancer. Journal of cellular biochemistry, 120(5), 8280-8290.

[65]. Chang, J.-E., Lee, D.-S., Ban, S.-W., Oh, J., Jung, M. Y., Kim, S.-H., . . . Jheon, S. (2018). Analysis of volatile organic compounds in exhaled breath for lung cancer diagnosis using a sensor system. Sensors and Actuators B: Chemical, 255, 800-807. doi: https://doi.org/10.1016/j.snb.2017.08.057

[66]. Wong, D. M., Fang, C. Y., Chen, L. Y., Chiu, C. I., Chou, T. I., Wu, C. C., . . . Tang, K. T. (2018, 13-17 April 2018). Development of a breath detection method based E-nose system for lung cancer identification. Paper presented at the 2018 IEEE International Conference on Applied System Invention (ICASI).

[67]. Madara, T., Māris, B., Gunta, S., Normunds, J., & Immanuels, T. (2017). Detection of lung cancer in exhaled breath with an electronic nose using support vector machine analysis. Journal of breath research, 11(3), 036009.

[68]. Shehada, N., Cancilla, J. C., Torrecilla, J. S., Pariente, E. S., Brönstrup, G., Christiansen, S., . . . Liran, O. (2016). Silicon nanowire sensors enable diagnosis of patients via exhaled breath. ACS nano, 10(7), 7047-7057.

[69]. Capuano, R., Martinelli, E., Ghezzi, S., Paolesse, R., Natale, C. D., Amico, A. D., . . . Pennazza, G. (2014, 2-5 Nov. 2014). An Investigation about the origin of the lung cancer signalling VOCs in breath. Paper presented at the IEEE SENSORS 2014 Proceedings.

[70]. Mazzone, P. J., Wang, X.-F., Xu, Y., Mekhail, T., Beukemann, M. C., Na, J., . . . Sasidhar, M. (2012). Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer. Journal of Thoracic Oncology, 7(1), 137-142. doi: https://doi.org/10.1097/JTO.0b013e318233d80f

[71]. Santonico, M., Lucantoni, G., Pennazza, G., Capuano, R., Galluccio, G., Roscioni, C., . . . Paolesse, R. (2012). In situ detection of lung cancer volatile fingerprints using bronchoscopic air-sampling. Lung Cancer, 77(1), 46-50.

[72]. Peng, G., Tisch, U., Adams, O., Hakim, M., Shehada, N., Broza, Y. Y., . . . Haick, H. (2009). Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nature Nanotechnology, 4, 669. doi: 10.1038/nnano.2009.235

[73]. Adetiba, E., Adebiyi, M. O., & Thakur, S. (2017). Breathogenomics: a computational architecture for screening, early diagnosis and genotyping of lung cancer. Paper presented at the International Conference on Bioinformatics and Biomedical Engineering.

[74]. Adetiba, E., & Olugbara, O. O. (2015). Lung cancer prediction using neural network ensemble with histogram of oriented gradient genomic features. The Scientific World Journal, 2015.

[75]. Daramola, S., Ekeh, J., Matthews, V., & Adetiba, E. (2011). Estimating an optimal backpropagation algorithm for training an ANN with the EGFR exon 19 nucleotide sequence: an electronic diagnostic basis for non-small cell lung cancer (NSCLC). Journal of Emerging Trends in Engineering and Applied Sciences, 2(1), 74-78.